1239eTiP BELLA: A phase II study of relacorilant plus nab-paclitaxel and bevacizumab in patients with platinum-resistant ovarian cancer

Journal article

Peer reviewed

D. Lorusso, B.J. Monk, J-Y. Park, N. Colombo, C.Y. Muller, J-W. Kim, L. Gladieff, A. Olawaiye, T. Van Gorp, A. Santaballa Bertrán, …

Annals of oncology, Vol.36, pp.S748-S748

09/2025

Files and links (1)

url

https://doi.org/10.1016/j.annonc.2025.11.012View

Published (Version of record) Open

1 Record Views

Title: 1239eTiP BELLA: A phase II study of relacorilant plus nab-paclitaxel and bevacizumab in patients with platinum-resistant ovarian cancer
Creators: D. Lorusso - Humanitas University
B.J. Monk - Florida Cancer Specialists & Research Institute
J-Y. Park - University of Ulsan
N. Colombo - European Institute of Oncology
C.Y. Muller - Gynecologic Oncology Group
J-W. Kim - Seoul National University Hospital
L. Gladieff - Institut universitaire du cancer de Toulouse Oncopole
A. Olawaiye - UPMC Hillman Cancer Center
T. Van Gorp - The European Academy of Gynaecological Surgery
A. Santaballa Bertrán - Hospital Universitari i Politècnic La Fe
R. Felberbaum - Kempten University of Applied Sciences
L. Bodnar - Centrum Onkologii
L. Fariñas Madrid - CIBBIM-Nanomedicine
P.H. Thaker - Washington University in St. Louis
H.I. Pashova - Corcept Therapeutics
B.K. Yadav - Corcept Therapeutics
S. Pai - Corcept Therapeutics
A. Mallen - Minnesota Oncology
Publication Details: Annals of oncology, Vol.36, pp.S748-S748
Publisher: Elsevier Ltd
Identifiers: 991006237232402656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article